Oklahoma biotech startup seeks to make predictive tests for lupusPublished: Wednesday, December 27, 2017 By: Scott Meacham Source: NewsOK
The holiday season is a time of hope, optimism, and belief in all possibilities and, for some, even the belief in impossibilities.
In our line of business at i2E, we regularly work shoulder to shoulder with Oklahoma-based startups and entrepreneurs who battle the seemingly impossible all year long. These people don't take no for an answer. They don't stop, and they don't quit.
That's why it is so rewarding for i2E to be the lead investor on a first-round funding to assist Progentec Diagnostics in moving its technology for predicting the onset of lupus flares closer to commercialization. Even more satisfying is that Mayo Clinic Ventures is a co-investor in the round.
Progentec's technologies, which have been licensed from the Oklahoma Medical Research Foundation (OMRF), are used to create highly accurate tests for early diagnosis of lupus as well as predictive tests for lupus flares.
“There is a big unmet need in screening the right people and managing them early,” said Progentec CEO and President Mohan Purushothaman. “It is very tough today; there is no good screening test to classify whether a patient has lupus or not. Most people only know they have lupus when they get a flare or when their doctor finds something indicative of lupus as part of their physical.”